Intracerebroventricular treatment with an antisense oligodeoxynucleotide to κ-opioid receptors inhibited κ-agonist-induced analgesia in rats
Reference (33)
- et al.
Receptor selectivity of i.c.v. morphine in the rat cold water tail-flick test
Drug Alcoh. Dep.
(1994) - et al.
Blockage of U50, 488H analgesia by antisense oligodeoxynucleotides to a κ-opioid receptor
Eur. J. Pharmacol.
(1994) - et al.
Primary structures and expression from cDNAs of rat opioid receptor δ- and μ-subtypes
FEBS Lett.
(1993) - et al.
Long term κ-opioid receptor blockade following nor-binaltorphimine
Eur. J. Pharmacol.
(1992) - et al.
Cloning and expression of a cDNA for the rat kappa-opioid receptor
FEBS Lett.
(1993) - et al.
cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for κ-subtype-selective ligands
FEBS Lett.
(1993) - et al.
Rat cold-water tail-flick: a novel analgesic test that distinguishes opioid agonists from mixed agonist-antagonists
Eur. J. Pharmacol.
(1985) - et al.
Naltrindole, a highly selective and potent non-peptide δ opioid receptor agonist
Eur. J. Pharmacol.
(1988) - et al.
Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor
Neuron
(1994) - et al.
Cloning and pharmacological characterization of a rat μ opioid receptor
Neuron
(1993)
Antisense oligunucleotide strategies in neuropharmacology
Trends Pharmacol. Sci.
Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates
Neurosci. Lett.
Isobolographic superadditivity between delta and mu opioid agonists in the rat depends on the ratio of compounds, the mu agonist and the analgesic assay used
J. Pharmacol. Exp. Ther.
Molecular cloning and functional expression of a μ-opioid receptor from rat brain
Mol. Pharmacol.
Molecular cloning of a rat κ-opioid receptor reveals sequence similarities to the μ and δ opioid receptors
Biochem. J.
Cloning of a delta opioid receptor by functional expression
Science
Cited by (45)
An antisense oligodeoxynucleotide to the mu opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice
2006, NeuroscienceCitation Excerpt :Two i.c.v. infusions of MOR AS ODN produced no change in baseline behavior compared with either i.c.v. saline or mismatch ODN control. Although the magnitude of MOR knockdown following two AS infusions is unknown, several studies using AS ODNs have shown that the analgesic effects of opioids are markedly reduced following as few as three intermittent AS ODN infusions (Adams et al., 1994; Zhou et al., 1994; Chen et al., 1995). The present findings of unchanged baseline data complement previous findings from our laboratory using the nonselective opioid receptor antagonist naltrexone in an administration paradigm that continuously blocked MORs in wild-type C57BL/6J mice (Hummel et al., 2004a) and an investigation using MOR knockout mice performed by Hall et al. (2004), but contradict findings in MOR-1 C57BL/6J knockouts (Hummel et al., 2004a).
Placenta ingestion by rats enhances δ- and κ-opioid antinociception, but suppresses μ-opioid antinociception
2004, Brain ResearchCitation Excerpt :Furthermore, the κ-receptor-specific nature of spiradoline antinociception can be asserted on the basis of its reversibility by κ-selective antagonism. This has been demonstrated both with conventional pharmacological strategies and with molecular (antisense) techniques [4,8,60]. These results indicate that the antinociceptive effects of spiradoline are mediated exclusively at the κ receptor, and together with evidence that POEF decreases the μ antinociception generated by DAMGO (Experiment 2), make it very likely that the enhancing action of POEF on antinociception induced by the low dose of spiradoline represents a κ, and not a μ, effect.
Ten years of antisense inhibition of brain G-protein-coupled receptor function
2003, Brain Research ReviewsChapter I Opioid receptors
2002, Handbook of Chemical NeuroanatomyThe diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system
2002, Pharmacology and TherapeuticsCitation Excerpt :The latest molecular advances implicating opioid receptor modulation of blood pressure make use of antisense oligodeoxynucleotide (ODN) technology. Antisense ODNs are small DNA fragments that are constructed to be complementary to a defined nucleotide sequence of a specific mRNA (Matteucci & Wagner, 1996; Adams et al., 1994; Chien, C. C. et al., 1994). Recently, these molecular agents have been used to investigate the involvement of opioids in blood pressure regulation.
This work was supported by Grants T32 DA07237, DA00376 and DA04745 from the National Institute on Drug Abuse.